Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174448| Title: | The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial |
| Author: | Chaccour, Carlos Ruiz Castillo, Paula Richardson, Mary-Ann Moncunill, Gemma Casellas, Aina Carmona Torre, Francisco Giráldez, Miriam Schwartz Mota, Juana Yuste, José R. Azanza, José Ramón Fernández, Miriam Reina, Gabriel Dobaño, Carlota, 1969- Brew, Joe Sadaba, Belen Hammann, Felix Rabinovich, Regina |
| Keywords: | SARS-CoV-2 Medicaments antivírics SARS-CoV-2 Antiviral agents |
| Issue Date: | 8-Jun-2020 |
| Publisher: | BioMed Central |
| Abstract: | Objectives: The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test from nasopharyngeal swab at day 7 post-treatment. |
| Note: | Reproducció del document publicat a: http://dx.doi.org/10.1186/s13063-020-04421-z |
| It is part of: | Trials, 2020, vol. 21 |
| URI: | http://hdl.handle.net/2445/174448 |
| Related resource: | http://dx.doi.org/10.1186/s13063-020-04421-z |
| ISSN: | 1745-6215 |
| Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Chaccour_C_Trials_2020.pdf | 444.54 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
